Cardiovascular diseases remain the leading cause of mortality worldwide, imposing an immense burden on healthcare systems and societies. Among these conditions, atherosclerosis stands out as the fundamental pathological process, forming the substrate for acute events such as myocardial infarction and stroke. Traditionally viewed as a lipid storage disorder, atherosclerosis is now increasingly recognized as a complex inflammatory disease involving both innate and adaptive immune responses. In this light, the role of immune cells, particularly T lymphocytes, is coming to the forefront, reshaping our understanding of disease mechanisms and therapeutic possibilities.
Among the diverse immune cell populations present within atherosclerotic plaques, CD8+ T cells have emerged as critical players. These cytotoxic lymphocytes are notably the most clonally expanded adaptive immune cells detected in human atherosclerotic lesions, suggesting their selective enrichment and potential functional relevance. However, whether CD8+ T cells exacerbate the disease by promoting inflammation and tissue damage or instead perform protective immunoregulatory functions remains a topic of intense investigation and debate.
Recent advances in single-cell transcriptomics, cytometry, and animal models have allowed for detailed characterization of CD8+ T cells during different stages of atherosclerosis. Phenotypically, CD8+ T cells display considerable heterogeneity within plaques; subsets express varying levels of activation markers, cytotoxic molecules such as perforin and granzyme B, and exhaustion markers including PD-1 and TIM-3. This diverse phenotypic landscape points to potential temporal and spatial shifts in their role, possibly contributing differently to plaque initiation, progression, or stabilization.
Functionally, CD8+ T cells participate in shaping the plaque microenvironment through their cytolytic activity and cytokine secretion profiles. By lysing infected or dysfunctional vascular cells, they may influence tissue remodeling and the ultimate stability of plaques. Conversely, excessive cytotoxicity could destabilize plaques, predisposing them to rupture and consequent clinical events such as myocardial infarction. Moreover, the cross-talk between CD8+ T cells and other immune components, such as macrophages and CD4+ T cells, further complicates the immune network within the atherosclerotic milieu.
Transcriptional profiling has uncovered key pathways modulating CD8+ T cell fate and function in atherosclerosis. Genes associated with oxidative metabolism, effector differentiation, and exhaustion signatures are differentially expressed depending on the plaque burden and systemic inflammatory state. This regulation underlines the plasticity of CD8+ T cells, which can adopt pro-inflammatory or regulatory phenotypes influenced by environmental cues in the atheroma microenvironment.
In addition to their intraplaque roles, CD8+ T cells may also contribute to broader systemic immune dysregulation observed in patients with atherosclerosis and its comorbidities. The interplay between metabolic disorders, chronic infections, and cardiovascular disease creates a complex pathophysiological context where CD8+ T cells may act as key mediators linking these conditions. Understanding these connections could unlock novel therapeutic strategies targeting systemic immune pathways.
Importantly, the role of CD8+ T cells is stage-specific. Early in atherogenesis, these cells can participate in antigen-specific responses aimed at restricting harmful lipid accumulation or dampening inflammation. However, during advanced disease, their chronic activation may result in dysfunctional cytotoxic responses contributing to plaque vulnerability. This dynamic evolution necessitates a nuanced approach to immunomodulation, carefully timed to the stage of disease.
Therapeutically, targeting CD8+ T cells presents both opportunities and challenges. Strategies aimed at curbing excessive cytotoxicity or reversing T cell exhaustion hold promise for mitigating plaque instability and reducing adverse cardiovascular outcomes. Conversely, approaches preserving or enhancing protective CD8+ T cell subsets could augment endogenous atheroprotective mechanisms. Novel immunotherapies, possibly integrating checkpoint inhibitors or metabolic modulators, are under active exploration in preclinical models.
The complexity of CD8+ T cell biology in atherosclerosis also raises critical research questions. What are the antigenic drivers of CD8+ T cell activation within plaques? How do systemic factors like hypercholesterolemia, diabetes, or infections modulate these responses? Could individualized immunoprofiling guide personalized therapies to optimize cardiovascular protection? Addressing these questions requires integrative studies combining clinical samples, advanced immunophenotyping, and functional assays.
Furthermore, recent work highlights the potential involvement of CD8+ T cells in secondary cardiovascular complications and in patients with comorbid autoimmune diseases. This underscores the broader impact of adaptive immune dysregulation beyond classical atherosclerosis and calls for comprehensive studies that factor in immune heterogeneity at the patient level.
As research continues to unravel the intricacies of CD8+ T cell participation in cardiovascular disease, there is growing optimism that immune-targeted therapies will become an integral part of clinical management. Such innovations could transform the prevention and treatment landscape for coronary artery disease by integrating immunological insights into existing cardiovascular paradigms.
In conclusion, CD8+ T cells occupy a pivotal position at the interface of immunology and cardiovascular pathology. Their dualistic roles, context-dependent functionalities, and intricate transcriptional programming render them both promising therapeutic targets and challenging subjects of study. Future research efforts should prioritize defining the molecular underpinnings governing CD8+ T cell behavior across disease stages, elucidating their interactions with systemic comorbidities, and developing specific interventions that can modulate their activity safely and effectively.
The potential of immunomodulation in cardiovascular medicine is expansive, and CD8+ T cells exemplify a critical frontier in this emerging field. By bridging fundamental immunology with translational cardiology, the insights gained promise to usher in novel strategies that could significantly reduce the global burden of atherosclerotic disease and improve patient outcomes worldwide.
Subject of Research: Role of CD8+ T cells in the pathogenesis and progression of atherosclerosis and coronary artery disease.
Article Title: CD8+ T cells in atherosclerosis and coronary artery disease.
Article References: Tandon, I., Yosri, M., Soliman, H. et al. CD8+ T cells in atherosclerosis and coronary artery disease. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01295-7
Image Credits: AI Generated
DOI: 10.1038/s41569-026-01295-7
Keywords: CD8+ T cells, atherosclerosis, coronary artery disease, adaptive immunity, cytotoxic T lymphocytes, plaque stability, immune modulation, cardiovascular immunology, transcriptional profiling.
Tags: adaptive immunity in atherosclerotic plaquesCD8+ T cells in atherosclerosisClonal expansion of CD8 T cellscytometry analysis in cardiovascular researchheterogeneity of T lymphocytes in heart diseaseimmune mechanismsimmune response in cardiovascular diseasesimmunoregulatory functions of CD8+ T cellsinflammation in myocardial infarctionrole of cytotoxic lymphocytes in heart diseasesingle-cell transcriptomics of immune cellstherapeutic targeting of T cells in atherosclerosis
